Other languages BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Market Closed - Deutsche Boerse AG Other stock markets 11:50:01 26/06/2024 am IST			5-day change	1st Jan Change
10.7 ^EUR	0.00%		-2.73%	-13.71%

26/06	Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing	MT
20/06	Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing	27/06
Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing	21/06
BeiGene présentera à l’EHA2024 de nouvelles données sur l’étude SEQUOIA évaluant la bithérapie BRUKINSA® plus vénétoclax dans le traitement de première intention de patients atteints de LLC/PLL à haut risque	15/06
EHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLL	15/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	14/06
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501	12/06
Beigene Issues Shares Under Incentive Schemes	12/06
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy	10/06
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	24/05
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India	21/05
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene	21/05
EHA2024: BeiGene präsentiert neues Hämatologie-Portfolio und Pipeline-Daten	16/05
BeiGene présente de nouvelles données de portefeuille et de pipeline d'hématologie à l'EHA2024	16/05
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	15/05
BeiGene meldet Finanzergebnisse für das erste Quartal 2024 und aktuelle Geschäftsentwicklungen	10/05
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	09/05
BeiGene presenta los resultados financieros del primer trimestre de 2024 y actualiza sus actividades	09/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Other languages

Filters